{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:16:25Z","timestamp":1778062585841,"version":"3.51.4"},"reference-count":108,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Phenylketonuria (PKU) is an autosomal recessive disorder characterised by an inborn error of phenylalanine (Phe) metabolism. Such errors are attributed to pathogenic gene variants causing phenylalanine hydroxylase (PAH) deficiency, impairing the hydroxylation of phenylalanine to tyrosine in the Phe metabolic pathway. This defect leads to plasma Phe concentrations above the normal range. If untreated, hyperphenylalaninemia can adversely affect brain function, leading to severe intellectual disability and seizures. Since 1969, the newborn dried blood spot test has remained the main method of early screening and diagnosis for PKU. The primary therapeutic management is a lifelong phenylalanine-restricted diet with the aim of decreasing plasma Phe levels. The recommended diet consists of avoiding high-protein foods such as meat, fish, eggs and nuts, and can be supplemented with high-protein medical formulas which are low in phenylalanine. Pharmacological interventions such as sapropterin, sepiapterin and pegvaliase can also be used as treatment adjuncts in patients with PKU. Currently, small-molecule inhibitors reducing renal phenylalanine reabsorption are being explored as a potential therapeutic intervention. Furthermore, novel gene-editing techniques are under evaluation as potential curative strategies, with preclinical studies showing promising results in correcting pathogenic phenylalanine hydroxylase variants. This non-systematic review synthesises current literature on the management of PKU, with a focus on dietary interventions and recommendations.<\/jats:p>","DOI":"10.3390\/nu18091347","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:28:23Z","timestamp":1777040903000},"page":"1347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nutritional and Therapeutic Strategies in Paediatric Phenylketonuria: A Narrative Literature Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Holly","family":"Jones","sequence":"first","affiliation":[{"name":"School of Medicine, University of Sunderland, Sunderland SR1 3SD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1149","authenticated-orcid":false,"given":"Eugen-Matthias","family":"Strehle","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Sunderland, Sunderland SR1 3SD, UK"},{"name":"The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","first-page":"4","article-title":"The Discovery of Phenylketonuria","volume":"407","year":"1994","journal-title":"Acta Paediatr. Suppl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ymgme.2011.08.017","article-title":"Diagnosis, Classification, and Genetics of Phenylketonuria and Tetrahydrobiopterin (BH4) Deficiencies","volume":"104","author":"Blau","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109125","DOI":"10.1016\/j.ymgme.2025.109125","article-title":"European Guidelines on Diagnosis and Treatment of Phenylketonuria: First Revision","volume":"145","author":"MacDonald","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","article-title":"A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants","volume":"32","author":"Guthrie","year":"1963","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The Complete European Guidelines on Phenylketonuria: Diagnosis and Treatment","volume":"12","author":"MacDonald","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(53)90473-5","article-title":"Influence of Phenylalanine Intake on Phenylketonuria","volume":"265","author":"Bickel","year":"1953","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101289","DOI":"10.1016\/j.gim.2024.101289","article-title":"Phenylalanine Hydroxylase Deficiency Diagnosis and Management: A 2023 Evidence-Based Clinical Guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Smith","year":"2025","journal-title":"Genet. Med."},{"key":"ref_9","unstructured":"National Institute for Health and Care Excellence (2026, March 13). Sapropterin for Treating Hyperphenylalaninaemia in Phenylketonuria. Available online: https:\/\/www.nice.org.uk\/guidance\/ta729."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"232640981557986","DOI":"10.1177\/2326409815579861","article-title":"Adherence to Treatment of Phenylketonuria: A Study in Southern Brazilian Patients","volume":"3","author":"Vieira","year":"2015","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000465529","article-title":"Micronutrients, Essential Fatty Acids and Bone Health in Phenylketonuria","volume":"70","author":"Demirdas","year":"2017","journal-title":"Ann. Nutr. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ymgme.2013.03.020","article-title":"White Matter Integrity and Executive Abilities in Individuals with Phenylketonuria","volume":"109","author":"Hershey","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1020158631102","article-title":"Phenylketonuria in Adulthood: A Collaborative Study","volume":"25","author":"Koch","year":"2002","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_14","first-page":"35","article-title":"Intellectual Development in 12-Year-Old Children Treated for Phenylketonuria","volume":"145","author":"Azen","year":"1991","journal-title":"Am. J. Dis. Child."},{"key":"ref_15","first-page":"54","article-title":"Treatment Adherence during Childhood in Individuals with Phenylketonuria: Early Signs of Treatment Discontinuation","volume":"11","author":"Araya","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jand.2012.05.004","article-title":"Food Products Made with Glycomacropeptide, a Low-Phenylalanine Whey Protein, Provide a New Alternative to Amino Acid-Based Medical Foods for Nutrition Management of Phenylketonuria","volume":"112","author":"Ney","year":"2012","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00431-025-06384-2","article-title":"Neurodevelopmental Assessment of Early Treated Children with Phenylketonuria: Insights from Griffith III Scales","volume":"184","author":"Abdelmoneim","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Daly, A., Evans, S., Pinto, A., Jackson, R., Ashmore, C., Rocha, J.C., and MacDonald, A. (2020). Preliminary Investigation to Review If a Glycomacropeptide Compared to L-Amino Acid Protein Substitute Alters the Pre- and Postprandial Amino Acid Profile in Children with Phenylketonuria. Nutrients, 12.","DOI":"10.3390\/nu12082443"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejcn.2016.166","article-title":"Long-Term Treatment of Phenylketonuria with a New Medical Food Containing Large Neutral Amino Acids","volume":"71","author":"Concolino","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/adc.74.5.412","article-title":"Factors Affecting the Variation in Plasma Phenylalanine in Patients with Phenylketonuria on Diet","volume":"74","author":"MacDonald","year":"1996","journal-title":"Arch. Dis. Child."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, Safety and Population Pharmacokinetics of Sapropterin in PKU Patients <4 Years: Results from the SPARK Open-Label, Multicentre, Randomized Phase IIIb Trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jpeds.2014.08.003","article-title":"Sapropterin Is Safe and Effective in Patients Less than 4-Years-Old with BH4-Responsive Phenylalanine Hydrolase Deficiency","volume":"165","author":"Shintaku","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1017\/S0012162205000861","article-title":"Cognitive Functions in Classic Phenylketonuria and Mild Hyperphenylalaninaemia: Experience in a Paediatric Population","volume":"47","author":"Artuch","year":"2005","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","article-title":"Phenylalanine Blood Levels and Clinical Outcomes in Phenylketonuria: A Systematic Literature Review and Meta-Analysis","volume":"92","author":"Waisbren","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","first-page":"39","article-title":"Weaning Practices in Phenylketonuria Vary between Health Professionals in Europe","volume":"18","author":"Pinto","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Burga\u00e7, E., \u00c7i\u00e7ek T\u00fcrk\u00f6z, E., Barut\u00e7u, A., Bulut, F.D., Kor, D., Kartal, T., Uzuno\u011flu, S., Kara, E., K\u00f6seci, B., and Kaplan, \u0130. (2025). Feeding Models in Classical Phenylketonuria: Do They Make a Difference in Infant Sleep?. Nutrients, 17.","DOI":"10.3390\/nu17183022"},{"key":"ref_27","first-page":"82","article-title":"Early Feeding Practices in Infants with Phenylketonuria across Europe","volume":"16","author":"Pinto","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","article-title":"PKU Dietary Handbook to Accompany PKU Guidelines","volume":"15","author":"MacDonald","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3345\/cep.2020.00059","article-title":"Components of Human Breast Milk: From Macronutrient to Microbiome and microRNA","volume":"63","author":"Kim","year":"2020","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e002066","DOI":"10.1136\/bmjpo-2023-002066","article-title":"Breast Feeding in Infants Diagnosed with Phenylketonuria (PKU): A Scoping Review","volume":"7","author":"Kalvala","year":"2023","journal-title":"BMJ Paediatr. Open"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Evans, S., Daly, A., Wildgoose, J., Cochrane, B., Chahal, S., Ashmore, C., Loveridge, N., and MacDonald, A. (2019). How Does Feeding Development and Progression onto Solid Foods in PKU Compare with Non-PKU Children During Weaning?. Nutrients, 11.","DOI":"10.3390\/nu11030529"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jhn.12510","article-title":"Fifteen Years of Using a Second Stage Protein Substitute for Weaning in Phenylketonuria: A Retrospective Study","volume":"31","author":"Evans","year":"2018","journal-title":"J. Hum. Nutr. Diet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0021-9258(18)70665-0","article-title":"The Utilization of Phenylalanine and Tyrosine for Protein Synthesis by Human Cells in Tissue Culture","volume":"228","author":"Eagle","year":"1957","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pinto, A., Ahring, K., Almeida, M.F., Ashmore, C., B\u00e9langer-Quintana, A., Burlina, A., Co\u015fkun, T., Daly, A., Van Dam, E., and Dursun, A. (2024). Longitudinal Dietary Intake Data in Patients with Phenylketonuria from Europe: The Impact of Age and Phenylketonuria Severity. Nutrients, 16.","DOI":"10.3390\/nu16172909"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13023-025-03840-y","article-title":"Current State of the Treatment Landscape of Phenylketonuria","volume":"20","author":"Nulmans","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10545-008-0937-3","article-title":"Phenylalanine Tolerance Can Already Reliably Be Assessed at the Age of 2 Years in Patients with PKU","volume":"32","author":"Dorgelo","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/21678707.2018.1536541","article-title":"Treatment Options and Dietary Supplements for Patients with Phenylketonuria","volume":"6","author":"Rocha","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Evans, S., Adam, S., Adams, S., Allen, H., Ashmore, C., Bailey, S., Banks, J., Churchill, H., Cochrane, B., and Cook, J. (2020). Uniformity of Food Protein Interpretation Amongst Dietitians for Patients with Phenylketonuria (PKU): 2020 UK National Consensus Statements. Nutrients, 12.","DOI":"10.3390\/nu12082205"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-277X.2006.00696.x","article-title":"The Determination of Phenylalanine Content of Foods Suitable for Phenylketonuria","volume":"19","author":"Weetch","year":"2006","journal-title":"J. Hum. Nutr. Diet."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Daly, A., Evans, S., Pinto, A., Ashmore, C., Rocha, J.C., and MacDonald, A. (2020). A 3 Year Longitudinal Prospective Review Examining the Dietary Profile and Contribution Made by Special Low Protein Foods to Energy and Macronutrient Intake in Children with Phenylketonuria. Nutrients, 12.","DOI":"10.3390\/nu12103153"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1025150901439","article-title":"Free Use of Fruits and Vegetables in Phenylketonuria","volume":"26","author":"MacDonald","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymgme.2012.04.016","article-title":"Positive Effect of a Simplified Diet on Blood Phenylalanine Control in Different Phenylketonuria Variants, Characterized by Newborn BH4 Loading Test and PAH Analysis","volume":"106","author":"Zimmermann","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1007\/PL00014375","article-title":"Diet and Compliance in Phenylketonuria","volume":"159","author":"MacDonald","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Pinto, A., Ahring, K., Almeida, M.F., Ashmore, C., B\u00e9langer-Quintana, A., Burlina, A., Co\u015fkun, T., Daly, A., van Dam, E., and Dursun, A. (2024). Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?. Nutrients, 16.","DOI":"10.3390\/nu16132064"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Daly, A., Evans, S., Chahal, S., Santra, S., Pinto, A., Gingell, C., Rocha, J.C., van Spronsen, F., Jackson, R., and MacDonald, A. (2019). The Effect of Glycomacropeptide versus Amino Acids on Phenylalanine and Tyrosine Variability over 24 Hours in Children with PKU: A Randomized Controlled Trial. Nutrients, 11.","DOI":"10.3390\/nu11030520"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Daly, A., Evans, S., Pinto, A., Ashmore, C., and MacDonald, A. (2021). Protein Substitutes in PKU; Their Historical Evolution. Nutrients, 13.","DOI":"10.3390\/nu13020484"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.rare.2025.100080","article-title":"The Exercising Patient with Phenylketonuria: Considerations and Research Recommendations","volume":"3","author":"Green","year":"2025","journal-title":"Rare"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10545-005-0122-x","article-title":"The Intake of Total Protein, Natural Protein and Protein Substitute and Growth of Height and Head Circumference in Dutch Infants with Phenylketonuria","volume":"28","author":"Hoeksma","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s10545-007-0549-3","article-title":"Growth and Body Composition in Children with Classical Phenylketonuria: Results in 34 Patients and Review of the Literature","volume":"30","author":"Huemer","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13370","DOI":"10.1111\/1541-4337.13370","article-title":"Glycomacropeptide: A Comprehensive Understanding of Its Major Biological Characteristics and Purification Methodologies","volume":"23","author":"Ebrahimi","year":"2024","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3945\/ajcn.2008.27280","article-title":"Improved Nutritional Management of Phenylketonuria by Using a Diet Containing Glycomacropeptide Compared with Amino Acids","volume":"89","author":"MacLeod","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3945\/ajcn.116.135293","article-title":"Glycomacropeptide for Nutritional Management of Phenylketonuria: A Randomized, Controlled, Crossover Trial","volume":"104","author":"Ney","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.rare.2025.100060","article-title":"Methodological Considerations and Implications for Appetite and Feeding Behaviour Research in PKU; Current Knowledge, Practical Application and Future Perspectives","volume":"3","author":"Green","year":"2025","journal-title":"Rare"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108607","DOI":"10.1016\/j.ymgme.2024.108607","article-title":"The Effects of Casein Glycomacropeptide on General Health Status in Children with PKU: A Randomized Crossover Trial","volume":"143","author":"Pinto","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Daly, A., Evans, S., Pinto, A., Jackson, R., Ashmore, C., Rocha, J.C., and MacDonald, A. (2020). The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria. Nutrients, 12.","DOI":"10.3390\/nu12092704"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Pinto, A., Daly, A., Rocha, J.C., Ashmore, C., Evans, S., Ilgaz, F., Hickson, M., and MacDonald, A. (2023). Natural Protein Intake in Children with Phenylketonuria: Prescription vs. Actual Intakes. Nutrients, 15.","DOI":"10.3390\/nu15234903"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/adc.65.5.472","article-title":"Intelligence and Quality of Dietary Treatment in Phenylketonuria","volume":"65","author":"Smith","year":"1990","journal-title":"Arch. Dis. Child."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wood, G., Evans, S., Pointon-Bell, K., Rocha, J.C., and MacDonald, A. (2020). Special Low Protein Foods in the UK: An Examination of Their Macronutrient Composition in Comparison to Regular Foods. Nutrients, 12.","DOI":"10.3390\/nu12061893"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-015-0378-7","article-title":"Special Low Protein Foods for Phenylketonuria: Availability in Europe and an Examination of Their Nutritional Profile","volume":"10","author":"Pena","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ejcn.2010.258","article-title":"Blood Phenylalanine Control in Phenylketonuria: A Survey of 10 European Centres","volume":"65","author":"Ahring","year":"2011","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wood, G., Pinto, A., Evans, S., Daly, A., Adams, S., Costelloe, S., Gribben, J., Ellerton, C., Emm, A., and Firman, S. (2021). Special Low Protein Foods Prescribed in England for PKU Patients: An Analysis of Prescribing Patterns and Cost. Nutrients, 13.","DOI":"10.3390\/nu13113977"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ymgme.2011.12.004","article-title":"Diet in Phenylketonuria: A Snapshot of Special Dietary Costs and Reimbursement Systems in 10 International Centers","volume":"105","author":"Dokoupil","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymgme.2013.08.008","article-title":"Main Issues in Micronutrient Supplementation in Phenylketonuria","volume":"110","author":"Lammardo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000363391","article-title":"The Micronutrient Status of Patients with Phenylketonuria on Dietary Treatment: An Ongoing Challenge","volume":"65","author":"Evans","year":"2014","journal-title":"Ann. Nutr. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10545-011-9412-7","article-title":"Bone Development in Children and Adolescents with PKU","volume":"35","author":"Mendes","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clnesp.2020.03.024","article-title":"Nutritional and Metabolic Parameters of Children and Adolescents with Phenylketonuria","volume":"37","author":"Laufer","year":"2020","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ahmadzadeh, M., Sohrab, G., Alaei, M., Eini-Zinab, H., Mohammadpour-Ahranjani, B., Rastgoo, S., and Namkhah, Z. (2022). Growth and Nutritional Status of Phenylketonuric Children and Adolescents. BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03715-2"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2020095","DOI":"10.1590\/1984-0462\/2021\/39\/2020095","article-title":"Metabolic Control and Body Composition of Children and Adolescents with Phenylketonuria","volume":"39","author":"Nogueira","year":"2021","journal-title":"Rev. Paul. Pediatr."},{"key":"ref_69","first-page":"107","article-title":"Treatment Adherence and Psychological Wellbeing in Maternal Carers of Children with Phenylketonuria (PKU)","volume":"37","author":"Medford","year":"2017","journal-title":"JIMD Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13023-021-02094-8","article-title":"Improving Phenylalanine and Micronutrients Status of Children with Phenylketonuria: A Pilot Randomized Study","volume":"16","author":"Zamani","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/eem.10.39","article-title":"Sapropterin Dihydrochloride for Phenylketonuria and Tetrahydrobiopterin Deficiency","volume":"5","author":"Blau","year":"2010","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_72","unstructured":"U.S. Food and Drug Administration (2019). Supplement Approval Letter: NDA 022181\/S-017."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13023-021-01968-1","article-title":"Long-Term Efficacy and Safety of Sapropterin in Patients Who Initiated Sapropterin at <4 Years of Age with Phenylketonuria: Results of the 3-Year Extension of the SPARK Open-Label, Multicentre, Randomised Phase IIIb Trial","volume":"16","author":"Muntau","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpeds.2007.02.017","article-title":"Assessment of Tetrahydrobiopterin (BH4) Responsiveness in Phenylketonuria","volume":"150","author":"Fiege","year":"2007","journal-title":"J. Pediatr."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lo Bianco, M., Leonardi, R., Migliore, A., Moliteo, E., Sciacca, M., Rinella, S., Pappalardo, M.G., La Spina, L., Messina, M., and Iacobacci, R. (2025). Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring. Nutrients, 17.","DOI":"10.3390\/nu17172892"},{"key":"ref_76","first-page":"101252","article-title":"Improving Sapropterin Administration Efficacy in PKU: Clinical Practice Case Studies","volume":"45","author":"Tosi","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_77","unstructured":"European Medicines Agency (2009). Kuvan: EPAR\u2014Product Information, European Medicines Agency."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/AOG.0000000000003768","article-title":"Management of Women with Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion, Number 802","volume":"135","author":"Rink","year":"2020","journal-title":"Obstet. Gynecol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymgme.2021.01.001","article-title":"Long-Term Preservation of Intellectual Functioning in Sapropterin-Treated Infants and Young Children with Phenylketonuria: A Seven-Year Analysis","volume":"132","author":"Waisbren","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/EC-20-0214","article-title":"Anthropometry and Bone Mineral Density in Treated and Untreated Hyperphenylalaninemia","volume":"9","author":"Bertoncel","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ilgaz, F., Pinto, A., G\u00f6kmen-\u00d6zel, H., Rocha, J.C., van Dam, E., Ahring, K., B\u00e9langer-Quintana, A., Dokoupil, K., Karabulut, E., and MacDonald, A. (2019). Long-Term Growth in Phenylketonuria: A Systematic Review and Meta-Analysis. Nutrients, 11.","DOI":"10.3390\/nu11092070"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bugi, M.-A., Jug\u0103naru, I., Simina, I.-E., Nicoar\u0103, D.-M., Cristun, L.-I., Brad, G.-F., Hu\u021banu, D., Isac, R., Kozma, K., and C\u00eernatu, D. (2024). Evaluating Therapy and Growth in Children with Phenylketonuria: A Retrospective Longitudinal Study from Two Romanian Centers. Medicina, 60.","DOI":"10.3390\/medicina60071185"},{"key":"ref_83","unstructured":"European Medicines Agency (2025). Sephience: EPAR\u2014Medicine Overview, European Medicines Agency."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(24)01556-3","article-title":"Effects of Oral Sepiapterin on Blood Phe Concentration in a Broad Range of Patients with Phenylketonuria (APHENITY): Results of an International, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"404","author":"Muntau","year":"2024","journal-title":"Lancet"},{"key":"ref_85","unstructured":"European Medicines Agency (2019). Palynziq: EPAR\u2014Public Assessment Report, European Medicines Agency."},{"key":"ref_86","first-page":"101084","article-title":"Pegvaliase for the Treatment of Phenylketonuria: Final Results of a Long-Term Phase 3 Clinical Trial Program","volume":"39","author":"Harding","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-023-02751-0","article-title":"Nutrition Management of PKU with Pegvaliase Therapy: Update of the Web-Based PKU Nutrition Management Guideline Recommendations","volume":"18","author":"Cunningham","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1177392819857089","DOI":"10.1177\/1177392819857089","article-title":"A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria","volume":"13","author":"Hydery","year":"2019","journal-title":"Drug Target Insights"},{"key":"ref_89","unstructured":"BioMarin Pharmaceutical (2026, March 13). Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12\u201317) with Phenylketonuria. Available online: https:\/\/clinicaltrials.biomarin.com\/clinical-trial\/study-to-evaluate-the-safety-and-efficacy-of-pegvaliase-in-adolescents-ages-12-17-with-phenylketonuria\/."},{"key":"ref_90","unstructured":"BioMarin Pharmaceutical (2026, March 13). BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ\u00ae (Pegvaliase-Pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism. Available online: https:\/\/www.biomarin.com\/news\/press-releases\/biomarin-announces-positive-pivotal-phase-3-data-for-palynziq-pegvaliase-pqpz-in-adolescents-with-phenylketonuria-at-15th-international-congress-of-inborn-errors-of-metabolism-2\/."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1089\/hum.2019.111","article-title":"State-of-the-Art 2019 on Gene Therapy for Phenylketonuria","volume":"30","author":"Schwank","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","article-title":"Evidence- and Consensus-Based Recommendations for the Use of Pegvaliase in Adults with Phenylketonuria","volume":"21","author":"Longo","year":"2019","journal-title":"Genet. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the Treatment of Phenylketonuria: Results of a Long-Term Phase 3 Clinical Trial Program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jimd.12651","article-title":"State-of-the-Art 2023 on Gene Therapy for Phenylketonuria","volume":"47","author":"Martinez","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_95","first-page":"247","article-title":"Gene Therapy for Phenylketonuria: Phenotypic Correction in a Genetically Deficient Mouse Model by Adenovirus-Mediated Hepatic Gene Transfer","volume":"1","author":"Fang","year":"1994","journal-title":"Gene Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.gt.3302678","article-title":"Complete Correction of Hyperphenylalaninemia Following Liver-Directed, Recombinant AAV2\/8 Vector-Mediated Gene Therapy in Murine Phenylketonuria","volume":"13","author":"Harding","year":"2006","journal-title":"Gene Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.gt.3302684","article-title":"Administration-Route and Gender-Independent Long-Term Therapeutic Correction of Phenylketonuria (PKU) in a Mouse Model by Recombinant Adeno-Associated Virus 8 Pseudotyped Vector-Mediated Gene Transfer","volume":"13","author":"Ding","year":"2006","journal-title":"Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/mt.2008.17","article-title":"Correction of Murine PKU Following AAV-Mediated Intramuscular Expression of a Complete Phenylalanine Hydroxylating System","volume":"16","author":"Ding","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_99","unstructured":"(2026, March 13). Homology Medicines Gene Therapy Clinical Study in Adult PKU (pheNIX), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03952156?tab=study."},{"key":"ref_100","unstructured":"BioMarin Pharmaceutical (2026, March 13). AAV Gene Therapy for Subjects with PKU, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04480567?tab=history&a=6#version-content-panel."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the State of the Science for Adeno-Associated Virus Integration: An Integrated Perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cacicedo, M.L., Weinl-Tenbruck, C., Frank, D., Limeres, M.J., Wirsching, S., Hilbert, K., Pasha Famian, M.A., Horscroft, N., Hennermann, J.B., and Zepp, F. (2022). Phenylalanine Hydroxylase mRNA Rescues the Phenylketonuria Phenotype in Mice. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.993298"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtn.2022.02.020","article-title":"Development of an mRNA Replacement Therapy for Phenylketonuria","volume":"28","author":"Vega","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e2401353","DOI":"10.1002\/adhm.202401353","article-title":"Current Advances and Material Innovations in the Search for Novel Treatments of Phenylketonuria","volume":"13","author":"Delbreil","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-Mediated CRISPR\/Cas9 Gene Editing in Murine Phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a Metabolic Liver Disease by in Vivo Genome Base Editing in Adult Mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omtm.2022.01.001","article-title":"A Universal Strategy for AAV Delivery of Base Editors to Correct Genetic Point Mutations in Neonatal PKU Mice","volume":"24","author":"Zhou","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Chen, H.-M., Resendes, R., Ghodssi, A., Sookiasian, D., Tian, M., Dollive, S., Adamson-Small, L., Avila, N., Tazearslan, C., and Thompson, J.F. (2020). Molecular Characterization of Precise In Vivo Targeted Gene Integration in Human Cells Using AAVHSC15. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233373"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/9\/1347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:47:57Z","timestamp":1778060877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/9\/1347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["nu18091347"],"URL":"https:\/\/doi.org\/10.3390\/nu18091347","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}